David Shaw’s Generate Biomedicines GENB Stock Holding History

David Shaw’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-95,000	Closed	-$1.19M	–	5354
2026 Q1	$1.19M	Buy	+95,000	New	+$1.16M	﹤0.01%	3319

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

David Shaw's GENB Position: Q2 2026 in Review

David Shaw sold out of Generate Biomedicines (GENB) in Q2 2026, closing a stake of 95,000 shares — an estimated $1.19M sold.

David Shaw first reported a position in GENB in Q1 2026 and held it in 1 quarter. The position peaked at $1.19M in Q1 2026. 85 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

David Shaw reported no remaining Generate Biomedicines position as of Q2 2026 after selling out during the quarter.
David Shaw sold 95,000 Generate Biomedicines shares in Q2 2026, an estimated $1.19M.
David Shaw first reported a position in Generate Biomedicines in Q1 2026 and held it in 1 quarter.
David Shaw's Generate Biomedicines position peaked at $1.19M in Q1 2026.
85 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.